Nasal sprays could be the future of treatment for Parkinson’s disease
Scientists at the University of York have made significant progress in the development of a nasal spray treatment for patients with Parkinson’s disease.
Researchers have developed a new gel that can adhere to tissue inside the nose alongside the drug levodopa, helping deliver treatment directly to the brain.
Levodopa is converted to dopamine in the brain, which makes-up for the deficit of dopamine-producing cells in Parkinson’s patients, and helps treat the symptoms of the disease. Over extended periods of time, however, levodopa becomes less effective, and increased doses are needed.
Increased dosage
Professor David Smith, from the University of York’s Department of Chemistry, said: “The current drug used for Parkinson’s Disease is effective to a point, but after a long period of use the body starts to breakdown the drug before it gets to the brain where it is most needed.
“This means increased dosage is necessary, and in later stages, sometimes, instead of tablets, the drug has to be injected. Investigations into nasal sprays have long been of interest as a more effective delivery because of its direct route to the brain via the nerves that service the nose, but the challenge here is to find a way of making it adhere to the nasal tissue long enough to release a good dosage of the drug.”
The researchers created a gel, loaded with levodopa, that could flow into the nose as a liquid and then rapidly change to a thin layer of gel inside the nose. The method was tested in animal models by a team at King’s College London, where levodopa was successfully released from the gel into the blood and directly to the brain.
Better uptake
Professor Smith said: “The results indicated that the gel gave the drug better adhesion inside the nose, which allowed for better levels of uptake into both the blood and brain.”
The team are now working to incorporate these materials in nasal spray devices to progress to clinical trials in humans. The approach may also be relevant to other neurodegenerative diseases such as Alzheimer’s.
Khuloud Al-Jamal, Professor of Drug Delivery and Nanomedicine from King’s College London, said: “Not only did the gel perform better than a simple solution, but the brain uptake was better than that achieved using intravenous injection of the drug. This suggests that nasal delivery of Parkinson’s drugs using this type of gel may have clinical relevance.”
Original Article: Step-closer to nasal spray drug delivery for Parkinson’s disease
More from: University of York | King’s College London
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Nasal spray drug delivery
- 5 people arrested after surge of suspected drug overdoses in Austin: Police
Police say a sixth person, 55-year-old Johnny Lee Wright, was arrested after surveillance video captured him delivering narcotics to Austin residents, KVUE reported. According to the APD, Wright has ...
- Foresees Rapid Growth in the Global Nasal Sprays Market, Predicted to Reach US$ 32.6 Billion by 2033
The global nasal sprays market is poised for unprecedented growth, with a projected value of US$ 32.6 billion by 2033, according to a groundbreaking study by Future Market Insights. This surge ...
- Pfizer sets up DTC marketing platform as Q1 sales beat expectations
The company plans to sell products such as its COVID treatment Paxlovid and a migraine nasal spray in this way ... case of Lilly—which launched LillyDirect in January to offer home delivery of ...
- After key Xhance approval, Optinose outlines plan to quadruple sales and reach profitability
CEO Ramy Mahmoud said because the company has patent protection for Xhance through 2026, it expects "long-tailed" cash flow.
- Hospitals to Distribute Narcan Nasal Spray at National Drug Take Back Day Events
Northwestern Medicine team members will distribute Narcan (naloxone) and provide education about opioid overdose prevention during National Prescription Drug Take Back Day from 10 a.m. to 2 p.m. on ...
Go deeper with Google Headlines on:
Nasal spray drug delivery
[google_news title=”” keyword=”nasal spray drug delivery” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Parkinson’s Disease
- Significant strides made in Nxera Pharma's oral compound for neurological conditions
Neurocrine Biosciences Inc. has initiated its phase 1 clinical study, marking a significant stride in the evaluation of NBI-1117567, an investigational small molecule, oral compound developed by Nxera ...
- Parkinson’s patient moves freely again after world-first implant of lab-grown cells into his brain
Parkinson’s patient Thomas Matsson was the first in the world to receive 7 million lab-grown brain cells in 2023. Today, he can smell and play sports.
- What is Parkinson's disease? Early detection and treatment help lead to better quality of life in old age
After an extended stay in the US, Ms. Aditi's reunion with her mother upon arriving in India did not turn out as planned. She noticed some significant and concerning shifts in her mother's behavior.
- Parkinson's Research News
Apr. 30, 2024 — Researchers have found a way to better control the preclinical generation of key neurons depleted in Parkinson's disease, pointing toward a new approach for a disease with no ...
- Rush Hospital patients seek out deep brain stimulation for Parkinson's Disease treatment
FDA-approved for more than 20 years, a RUSH neurosurgeon says he has patients seeking out Deep Brain Stimulation to treat Parkinson’s Disease, now that the technology and surgical techniques have ...
Go deeper with Google Headlines on:
Parkinson’s Disease
[google_news title=”” keyword=”Parkinson’s Disease” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]